ANI Pharmaceuticals is executing a successful transformation toward high-margin rare disease products, with revenue accelerating 43.8% year-over-year in 2026Q2 and gross margins expanding to 62.4%.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $2.70+23.9% vs $2.18 | $291M+3.6% vs $281M |
Q3 2026 Aug 7, 2026 | $2.21+8.3% vs $2.04 | $266M+2.3% vs $260M |
Q2 2026 May 8, 2026 | $2.05+60.2% vs $1.28 | $237M+14.4% vs $208M |
Q1 2026 Feb 27, 2026 | $2.33+17.1% vs $1.99 | $247M+6.9% vs $231M |
ANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outlook for Cortrophin Gel after pharmacy bottlenecks slowed the conversion of new patient cases into treatment.
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.04 per share a year ago.
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.
Benchmark ANIP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ANI Pharmaceuticals, Inc. (ANIP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $67.41 | $1.53B | 12.51 | 43.78% | 11.22% | 20% | 0.08% | |
| $20.14 | $6.43B | 45.82 | 8.05% | 4.62% | 82.23% | — | |
| $100.61 | $6.55B | 25.50 | 0.5% | 17.28% | 21.72% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $32.96 | $1.34B | 13.14 | 17.12% | 6.67% | 27.44% | 1.44% | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — |
ANI Pharmaceuticals, Inc. (ANIP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ANI Pharmaceuticals, Inc. (ANIP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 7, 2026·SEC
May 21, 2026·SEC
May 13, 2026·SEC
Get notified when ANIP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANI Pharmaceuticals, Inc. (ANIP) stock FAQ — growth, dividends, profitability & financials explained
ANI Pharmaceuticals, Inc. (ANIP) reported $1.04B in revenue over the trailing twelve months. Revenue was $883.4M in fiscal year 2025. That is 717728% more than the $0.1M of fiscal year 1998.
ANI Pharmaceuticals, Inc. (ANIP) grew revenue by 25.9% over the trailing twelve months, compared with the twelve months before.
Yes. ANI Pharmaceuticals, Inc. (ANIP) earned $116.8M in net income over the trailing twelve months (a 11.2% net margin).
ANI Pharmaceuticals, Inc. (ANIP) does not currently pay a meaningful dividend.
ANI Pharmaceuticals, Inc. (ANIP) had a return on equity (ROE) of 20.0% over the trailing twelve months. That is above the market's typical 10-15%.
ANI Pharmaceuticals, Inc. (ANIP) generated $191.8M in free cash flow over the trailing twelve months.
